

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal805sxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 4 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 6 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 7 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 8 JAN 30 Saved answer limit increased
NEWS 9 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
visualization results
NEWS 10 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 11 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 12 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 13 FEB 28 MEDLINE/LMEDLINE reload improves functionality
NEWS 14 FEB 28 TOXCENTER reloaded with enhancements
NEWS 15 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral
property data
NEWS 16 MAR 01 INSPEC reloaded and enhanced
NEWS 17 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18 MAR 08 X.25 communication option no longer available after June 2006
NEWS 19 MAR 22 EMBASE is now updated on a daily basis
NEWS 20 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC
thesaurus added in PCTFULL
NEWS 22 APR 04 STN AnaVist \$500 visualization usage credit offered

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:54:26 ON 11 APR 2006

=> file medline biosis caplus biotechno embase scisearch		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 13:55:07 ON 11 APR 2006

FILE 'BIOSIS' ENTERED AT 13:55:07 ON 11 APR 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 13:55:07 ON 11 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 13:55:07 ON 11 APR 2006

COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'EMBASE' ENTERED AT 13:55:07 ON 11 APR 2006

Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 13:55:07 ON 11 APR 2006

Copyright (c) 2006 The Thomson Corporation

=> s sos1

L1 951 SOS1

=> s sos-1

L2 266 SOS-1

=> s l1 and antisense

L3 15 L1 AND ANTISENSE

=> s l2 and antisense

L4 2 L2 AND ANTISENSE

=> s l3 or l4

L5 17 L3 OR L4

=> dup rem l5

PROCESSING COMPLETED FOR L5

L6 9 DUP REM L5 (8 DUPLICATES REMOVED)

=> d 1-9 ti

L6 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Genes showing altered expression in non-small cell lung cancers and their use in diagnosis

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Compositions of **Sos1** inhibitors and use for regulating tumor cell growth

L6 ANSWER 3 OF 9 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN
DUPLICATE

TI New approach to cancer therapy: The application of signal transduction to anti-cancer drug

L6 ANSWER 4 OF 9 MEDLINE on STN DUPLICATE 2

TI Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses.

L6 ANSWER 5 OF 9 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Analysis of differential downstream signaling between breast cancer cell lines overexpressing epidermal growth factor receptor and ErbB2.

L6 ANSWER 6 OF 9 MEDLINE on STN

TI Modulation of the immune response and tumor growth by activated Ras.

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Therapeutic methods for vascular injury using inhibition of the Ras signal transduction pathway

L6 ANSWER 8 OF 9 MEDLINE on STN DUPLICATE 3

TI IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.

L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

TI Proteins having a GDP exchange factor activity, nucleic acid sequences coding for said peptides, preparation and therapeutic and diagnostic uses of said nucleic acids and proteins

=> d ab

L6 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AB Genes that show altered levels of expression in non-small cell lung cancer and that can be used to diagnose the disease are identified. The genes or gene products may also be targets for drugs for treatment of the disease. A group of approx. 1400 genes showing cancer-specific up or down regulation is identified. **Antisense** nucleic acids and siRNAs are reported for some of these genes.

=> d ab 1-9

L6 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AB Genes that show altered levels of expression in non-small cell lung cancer and that can be used to diagnose the disease are identified. The genes or gene products may also be targets for drugs for treatment of the disease. A group of approx. 1400 genes showing cancer-specific up or down regulation is identified. **Antisense** nucleic acids and siRNAs are reported for some of these genes.

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AB The present invention provides inventive inhibitors of guanine nucleotide exchange factor **Sos1** include, but are not limited to, **antisense** mols., ribozymes, RNAi, antibodies or antibody fragments, proteins or polypeptides as well as small mols. Methods of using the compns. for modulating **Sos1** expression and for regulating cell growth, particularly tumor cell growth, are also provided.

L6 ANSWER 3 OF 9 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE

AB Although it has been widely known that extracellular signal-regulated kinase (ERK) pathway stimulates cell growth and have a protective effect from cell death, recent findings propose pro-apoptotic action of ERK phosphorylation. Since it was found that Vitamin K3 (VK3) or its analog was a potent growth inhibitor and inducer for ERK phosphorylation through specific pathway in cancer cell line, the critical role of ERK phosphorylation in growth inhibitory actions can be discussed. VK3 induced receptor tyrosine phosphorylation and occurred at growth inhibitory concentrations. The phosphorylation of growth factor receptor by VK3 was indicated to be functional, since these were connected with growth factor receptor-bound protein 2 (Grb2) and **SOS1**. The growth factor stimulated to induce cyclin D1 protein and increase DNA contents. In addition, ERK inhibitor antagonized increase of cyclin D1, suggesting that ERK phosphorylation by growth factor might play an

essential role for cell growth. By contrast, ERK phosphorylation by VK3 was more prolonged and intense than the signal induced by growth factors and the antagonize ERK phosphorylation protected from growth inhibition by VK3. The additional and extra ERK spot by VK3, compared with those obtained from growth factor, was detected on two dimensional gels, and this was completely and selectively antagonized by ERK inhibitor. Therefore, the overexpressed ERK phosphorylation was suggested to originate from the additional spot, which played a critical role in growth inhibitory action, despite ERK phosphorylation by growth factor had an essential association with cell growth. The new approach to consider the signal transduction can be one of the most favorite strategies for cancer therapy in the future.

L6 ANSWER 4 OF 9 MEDLINE on STN DUPLICATE 2
AB Hyaluronan (HA) is a large nonsulfated glycosaminoglycan and an important regulator of angiogenesis, in particular, the growth and migration of vascular endothelial cells. We have identified some of the key intermediates responsible for induction of mitogenesis and wound recovery. Treatment of bovine aortic endothelial cells with oligosaccharides of hyaluronan (o-HA) resulted in rapid tyrosine phosphorylation and plasma membrane translocation of phospholipase Cgamma1 (PLCgamma1). Cytoplasmic loading with inhibitory antibodies to PLCgamma1, Gbeta, and Galpha(i/o/t/z) inhibited activation of extracellular-regulated kinase 1/2 (ERK1/2). Treatment with the Galpha(i/o) inhibitor, pertussis toxin, reduced o-HA-induced PLCgamma1 tyrosine phosphorylation, protein kinase C (PKC) alpha and beta1/2 membrane translocation, ERK1/2 activation, mitogenesis, and wound recovery, suggesting a mechanism for o-HA-induced angiogenesis through G-proteins, PLCgamma1, and PKC. In particular, we demonstrated a possible role for PKCalpha in mitogenesis and PKCbeta1/2 in wound recovery. Using **antisense** oligonucleotides and the Ras farnesylation inhibitor FTI-277, we showed that o-HA-induced bovine aortic endothelial cell proliferation, wound recovery, and ERK1/2 activation were also partially dependent on Ras activation, and that o-HA-stimulated tyrosine phosphorylation of the adapter protein Shc, as well as its association with **Sos1**. Binding of Src to Shc was required for its activation and for Ras-dependent activation of ERK1/2, cell proliferation, and wound recovery. Neither Src nor Ras activation was inhibited by pertussis toxin, suggesting that their activation was independent of heterotrimeric G-proteins. However, the specific Src kinase inhibitor PP2 inhibited Gbeta subunit co-precipitation with PLCgamma1, suggesting a possible role for Src in activation of PLCgamma1 and interaction between two distinct o-HA-induced signaling pathways.

L6 ANSWER 5 OF 9 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

L6 ANSWER 6 OF 9 MEDLINE on STN
AB As a result of its transforming abilities, activated Ras is expressed in a great number of cancers. The ras mutation frequency varies between 95% in pancreatic cancer and 5% in breast cancer. In leukemia, the highest frequency (30%) is found in acute myeloid leukemia. The presence of ras mutations has been correlated with a poor prognosis and negative clinical outcome. This suggests that mutated Ras activates mechanisms, which favor tumor growth, enhance the metastatic capacity of tumors or modulate tumor-specific immune responses. Several new functions of Ras, such as downregulation of major histocompatibility complex molecules, upregulation of certain cytokines, growth factors and degradative enzymes have been uncovered in the last decade. Additionally, mutated Ras can also serve as a primary target for the development of immunotherapy or drug therapy. This review will discuss the mechanisms by which Ras expressing tumors are able to evade destruction by the immune system and enhance their growth and metastatic potential. It will further elaborate on the attempts to develop successful immunotherapy and drug therapy targeting Ras expressing tumors.

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AB Methods are provided for treating disorders associated with vascular injury from mech. stimuli, including restenosis, atherosclerosis and reperfusion injury. In one embodiment of the invention gene therapy techniques are applied using genes encoding a variety of proteins that play key roles in transducing an extracellular signal through to the nucleus, including src, Ras, MEKK and JNK. These proteins are mutated such that they are rendered signal transduction incompetent, thus abrogating their ability to induce a cellular response. The invention further encompasses viral gene therapy vectors containing genes encoding these signaling incompetent mutants and pharmaceutical compns. Addnl. embodiments of the invention encompass alternative means of inhibiting the key signal transduction pathways related to mech. injury. One alternative includes the use of **antisense** versions of genes encoding key proteins such as src, Ras, MEKK, JNK and the like. Chemical compds. acting as enzymic inhibitors or disrupters of protein-protein interactions are also contemplated by the invention.

L6 ANSWER 8 OF 9 MEDLINE on STN DUPLICATE 3

AB IL-6 mediates growth of some human multiple myeloma (MM) cells and IL-6-dependent cell lines. Although three IL-6 signaling pathways (STAT1, STAT3, and Ras-dependent MAPK cascade) have been reported, cascades mediating IL-6-triggered growth of MM cells and cell lines are not defined. In this study, we therefore characterized IL-6 signaling cascades in MM cell lines, MM patient cells, and IL-6-dependent B9 cells to determine which pathway mediates IL-6-dependent growth. IL-6 induced phosphorylation of JAK kinases and gp130, regardless of the proliferative response of MM cells to this growth factor. Accordingly, we next examined downstream IL-6 signaling via the STAT3, STAT1, and Ras-dependent mitogen-activated protein kinase (MAPK) cascades. IL-6 triggered phosphorylation of STAT1 and/or STAT3 in MM cells independent of their proliferative response to IL-6. In contrast, IL-6 induced phosphorylation of Shc and its association with **Sos1**, as well as phosphorylation of MAPK, only in MM cells and B9 cells that proliferated in response to IL-6. Moreover, MAPK **antisense**, but not sense, oligonucleotide inhibited IL-6-induced proliferation of these cells. These data suggest that STAT1 and/or STAT3 activation may occur independently of the proliferative response to IL-6, and that activation of the MAPK cascade is an important distal pathway for IL-6-mediated growth.

L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AB The cDNAs for human GDP exchange factors GRF, **SOS1**, and SOS2 are presented. Peptides derived from these proteins, antibodies to the proteins, and (**antisense**) nucleic acids related to these cDNAs can be used as therapeutics, e.g., in cancer treatment, or in diagnosis (no data). GRF and peptides derived from GRF were shown to promote GDP-GTP exchange of p21ras in CHO cells and *Saccharomyces cerevisiae*. The cDNA for GRF was used as a hybridization probe to isolate the **SOS1** and SOS2 cDNAs from a placental cDNA library. The genes for GRF, **SOS1**, and SOS2 were mapped to 15q2.4, 4q21., and 14q2.2, resp.

=> d 9

L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1994:126966 CAPLUS

DN 120:126966

TI Proteins having a GDP exchange factor activity, nucleic acid sequences coding for said peptides, preparation and therapeutic and diagnostic uses of said nucleic acids and proteins

IN Schweighoffer, Fabien; Tocque, Bruno

PA Rhone-Poulenc Rorer SA, Fr.

SO PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9321314	A1	19931028	WO 1993-FR382	19930419
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	FR 2690162	A1	19931022	FR 1992-4827	19920421
	FR 2690162	B1	19950804		
	EP 637334	A1	19950208	EP 1993-911529	19930419
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 07505774	T2	19950629	JP 1993-518065	19930419
	JP 3681384	B2	20050810		
	US 5656595	A	19970812	US 1994-318831	19941019
PRAI	FR 1992-4827	A	19920421		
	WO 1993-FR382	W	19930419		

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	32.91	33.12

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.75	-3.75

FILE 'STNGUIDE' ENTERED AT 14:01:18 ON 11 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 7, 2006 (20060407/UP).

=> SET NOTICE DISPLAY 1

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> set auhelp off; set smart off; set msteps off; set expand cont; set audit off;
del sel y

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

=> FILE CAPLUS,WPINDEX

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.18	33.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
--	------------	-------

CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-3.75

FILE 'CAPLUS' ENTERED AT 14:03:14 ON 11 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Apr 2006 VOL 144 ISS 16
FILE LAST UPDATED: 10 Apr 2006 (20060410/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S US 1994-318831/PN,APPS

```
      0 US 1994-318831/PN
        (US94318831/PN)
      1 US94-318831/AP
      0 US94-318831/PRN
      1 US 1994-318831/APPS
        (US94-318831/AP,PRN)
L7      1 US 1994-318831/PN,APPS
```

=> FILE INPADOC

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	6.31	39.61
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-3.75

FILE 'INPADOC' ENTERED AT 14:03:16 ON 11 APR 2006
COPYRIGHT (C) 2006 European Patent Office, Vienna (EPO)

FILE LAST UPDATED: 06 APR 2006 <20060406/UP>
06 APR 2006 <20060406/UPLS>
MOST RECENT INPADOC WEEK: 200614
FILE COVERS 1968 TO DATE.

>>> FOR STATISTIC OF CURRENT WEEK'S NEW ENTRIES,
ENTER HELP UPS <<<

>>> STATISTIC FOR UPDATES OF PUBLICATION/PATENT KIND CODES
A. SORTED BY COUNTRY:

<http://www.stn-international.de/stndatabases/details/inpadoc/fkd1>

B. SORTED BY DATE:

[<<<](http://www.stn-international.de/stndatabases/details/inpadoc/fkd2)

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html <<<
>>> NEW IPC8 SEARCH, DISPLAY, AND SELECT ENHANCEMENTS ! --> SEE NEWS <<<
>>> A thesaurus is available in the /IPC search field --> SEE NEWS <<<
>>> FOR CHANGES IN INPADOC SEE HELP CHANGE (last updated February 16, 2006) <<<
>>> IPC reclassification data according to IPC8 (prior to Inpadoc week 2006/02)
is now available for display. The search index will be build successively
on a patent country basis. <<<

=> TRA L7 PN

L8 TRANSFER L7 1- PN : 6 TERMS
L9 5 L8

=>

=> S L9 AND US/PC

 4498813 US/PC
L10 1 L9 AND US/PC

=> SEL PN

E1 THROUGH E1 ASSIGNED

=> S L9 AND ZA/PC

 206895 ZA/PC
L11 0 L9 AND ZA/PC

=> SEL PN

L11 HAS NO ANSWERS

=> S L9 AND EP/PC AND EN/LA

 1644953 EP/PC
 3082751 EN/LA
L12 0 L9 AND EP/PC AND EN/LA

=> SEL PN

L12 HAS NO ANSWERS

=> S L9 AND WO/PC AND EN/LA

 1101091 WO/PC
 3082751 EN/LA
L13 0 L9 AND WO/PC AND EN/LA

=> SEL PN

L13 HAS NO ANSWERS

=> S L9 AND AU/PC

 936853 AU/PC
L14 0 L9 AND AU/PC

=> SEL PN

L14 HAS NO ANSWERS

=> S L9 AND CA/PC AND EN/LA

939081 CA/PC
3082751 EN/LA

L15 0 L9 AND CA/PC AND EN/LA

=> SEL PN

L15 HAS NO ANSWERS

=> D SELECT

E1 1 US5656595/PN

=>

Do you want to retrieve bibliographic & abstract data for these patent numbers from the CAplus and WPINDEX files (Y/N)?

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> logoff y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
6.44	58.27

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-3.75

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 14:07:38 ON 11 APR 2006

WEST Search History

DATE: Tuesday, April 11, 2006

Hide?	Set Name	Query	Hit Count
-------	----------	-------	-----------

DB=USPT; PLUR=YES; OP=ADJ

<input type="checkbox"/>	L7	son of sevenless	0
<input type="checkbox"/>	L6	son of sevenless	0
<input type="checkbox"/>	L5	L1 and anribozyme	0

DB=PGPB; PLUR=YES; OP=ADJ

<input type="checkbox"/>	L4	L3 and antisense	58
<input type="checkbox"/>	L3	sos1 or sos-1	97

DB=USPT; PLUR=YES; OP=ADJ

<input type="checkbox"/>	L2	L1 and antisense	22
<input type="checkbox"/>	L1	SOS1 or SOS-1	72

END OF SEARCH HISTORY